L 696229
Modify Date: 2024-01-05 22:11:27
L 696229 structure
|
Common Name | L 696229 | ||
|---|---|---|---|---|
| CAS Number | 135525-71-2 | Molecular Weight | 282.33700 | |
| Density | 1.149g/cm3 | Boiling Point | 496.5ºC at 760mmHg | |
| Molecular Formula | C17H18N2O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 254.1ºC | |
Use of L 696229L 696229 is a specific inhibitor ofhuman immunodeficiency virus type 1 (HIV-1)reverse transcriptase (RT) activity that possesses antiviral activity[1]. |
| Name | 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-1H-pyridin-2-one |
|---|---|
| Synonym | More Synonyms |
| Description | L 696229 is a specific inhibitor ofhuman immunodeficiency virus type 1 (HIV-1)reverse transcriptase (RT) activity that possesses antiviral activity[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.149g/cm3 |
|---|---|
| Boiling Point | 496.5ºC at 760mmHg |
| Molecular Formula | C17H18N2O2 |
| Molecular Weight | 282.33700 |
| Flash Point | 254.1ºC |
| Exact Mass | 282.13700 |
| PSA | 59.15000 |
| LogP | 3.58440 |
| Vapour Pressure | 5.37E-10mmHg at 25°C |
| Index of Refraction | 1.58 |
|
~93%
L 696229 CAS#:135525-71-2 |
| Literature: Saari; Hoffman; Wai; Fisher; Rooney; Smith; Thomas; Goldman; O'Brien; Nunberg; Quintero; Schleif; Emini; Stern; Anderson Journal of Medicinal Chemistry, 1991 , vol. 34, # 9 p. 2922 - 2925 |
|
~%
L 696229 CAS#:135525-71-2 |
| Literature: Saari; Hoffman; Wai; Fisher; Rooney; Smith; Thomas; Goldman; O'Brien; Nunberg; Quintero; Schleif; Emini; Stern; Anderson Journal of Medicinal Chemistry, 1991 , vol. 34, # 9 p. 2922 - 2925 |
|
~%
L 696229 CAS#:135525-71-2 |
| Literature: Saari; Hoffman; Wai; Fisher; Rooney; Smith; Thomas; Goldman; O'Brien; Nunberg; Quintero; Schleif; Emini; Stern; Anderson Journal of Medicinal Chemistry, 1991 , vol. 34, # 9 p. 2922 - 2925 |
|
~%
L 696229 CAS#:135525-71-2 |
| Literature: Hoffman; Smith; Rooney; Fisher; Wai; Thomas; Bamberger; Barnes; Williams; Jones; Olson; O'Brien; Goldman; Nunberg; Quintero; Schleif; Emini; Anderson Journal of Medicinal Chemistry, 1993 , vol. 36, # 8 p. 953 - 966 |
|
~%
L 696229 CAS#:135525-71-2 |
| Literature: Saari; Hoffman; Wai; Fisher; Rooney; Smith; Thomas; Goldman; O'Brien; Nunberg; Quintero; Schleif; Emini; Stern; Anderson Journal of Medicinal Chemistry, 1991 , vol. 34, # 9 p. 2922 - 2925 |
|
~%
L 696229 CAS#:135525-71-2 |
| Literature: Saari; Hoffman; Wai; Fisher; Rooney; Smith; Thomas; Goldman; O'Brien; Nunberg; Quintero; Schleif; Emini; Stern; Anderson Journal of Medicinal Chemistry, 1991 , vol. 34, # 9 p. 2922 - 2925 |
![3-[2-(benzoxazol-2-yl)-ethenyl]-5-ethyl-6-methyl-2-(1H)-pyridinone structure](https://www.chemsrc.com/caspic/494/139548-67-7.png)
![2-[2(R/S)-hydroxy-2-(2-methoxy-5-ethyl-6-methylpyridin-3-yl)ethyl]benzoxazole structure](https://www.chemsrc.com/caspic/055/139393-87-6.png)
| 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2(1H)-one |
| 2-pyridinol,3-[2-(2-benzoxazolyl)ethyl]-5-ethyl-6-methyl |
| 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone |